Department of Public Health and Primary Care, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Institute of Primary Health Care (BIHAM), University of Bern, Bern CH-3012, Switzerland.
Age Ageing. 2022 Jan 6;51(1). doi: 10.1093/ageing/afab192.
translation of the available evidence concerning primary cardiovascular prevention into clinical guidance for the heterogeneous population of older adults is challenging. With this review, we aimed to give an overview of the thresholds and targets of antihypertensive drug therapy for older adults in currently used guidelines on primary cardiovascular prevention. Secondly, we evaluated the relationship between the advised targets and guideline characteristics, including guideline quality.
we systematically searched PubMed, Embase, Emcare and five guideline databases. We selected guidelines with (i) numerical thresholds for the initiation or target values of antihypertensive drug therapy in context of primary prevention (January 2008-July 2020) and (ii) specific advice concerning antihypertensive drug therapy in older adults. We extracted the recommendations and appraised the quality of included guidelines with the AGREE II instrument.
thirty-four guidelines provided recommendations concerning antihypertensive drug therapy in older adults. Twenty advised a higher target of systolic blood pressure (SBP) for octogenarians in comparison with the general population and three advised a lower target. Over half of the guidelines (n = 18) recommended to target a SBP <150 mmHg in the oldest old, while four endorsed targets of SBP lower than 130 or 120 mmHg. Although many guidelines acknowledged frailty, only three gave specific thresholds and targets. Guideline characteristics, including methodological quality, were not related with the recommended targets.
the ongoing debate concerning targets of antihypertensive treatment in older adults, is reflected in an inconsistency of recommendations across guidelines. Recommended targets are largely set on chronological rather than biological age.
将有关主要心血管预防的现有证据转化为针对老年人群体异质性的临床指导具有挑战性。通过本次综述,我们旨在概述目前主要心血管预防指南中用于老年患者的降压药物治疗的阈值和目标。其次,我们评估了所建议的目标与指南特征之间的关系,包括指南质量。
我们系统地检索了 PubMed、Embase、Emcare 和五个指南数据库。我们选择了(i)在初级预防背景下启动或降压药物治疗目标值的数值阈值(2008 年 1 月至 2020 年 7 月)和(ii)针对老年人降压药物治疗的具体建议的指南。我们提取了建议,并使用 AGREE II 工具评估了纳入指南的质量。
34 项指南针对老年人的降压药物治疗提供了建议。20 项指南建议 80 岁以上老年人的收缩压(SBP)目标值高于一般人群,3 项指南建议较低的目标值。超过一半的指南(n=18)建议将最年长的老年人的 SBP 目标值设定为<150mmHg,而 4 项指南则支持 SBP 目标值低于 130 或 120mmHg。尽管许多指南承认衰弱,但只有 3 项指南给出了具体的阈值和目标值。指南特征,包括方法学质量,与建议的目标值无关。
目前主要心血管预防指南中降压治疗目标值的持续争论反映了指南之间建议的不一致性。建议的目标主要基于年龄而不是生物年龄。